KRAS and cancer: Inhibition of the phosphatase SHP2 exhibits therapeutic potential in cancers dependent on receptor tyrosine kinases and mutated KRAS signaling, as SHP2 plays a critical role in mediating MAPK signaling in cancer cells15,16.